Poly(adenosine diphosphate ribose) polymerase inhibition in isocitrate dehydrogenase 1 and 2-mutant tumors: Bridging science with the clinic.

In this issue of , Cecchini et al. report findings from a phase 2 open-label trial of olaparib in 30 patients with advanced cholangiocarcinoma and IDH1/2 mutations. While the trial did not meet its primary endpoint, a subset of patients experienced prolonged clinical benefit, highlighting the potential for alternative therapeutic strategies involving PARP inhibitors in future clinical trials.